Objective: To determine types and frequency of side effects of antihypertensive drugs in patients with diabetes mellitus (DM) type 2 and hypertension. Subjects and Methods: We performed a prospective study of 79 patients with DM type 2 and hypertension, randomly selected by systematic sampling, who were followed over a period of six months. Patients were assessed at baseline and once a month measuring following parameters: types of used antihypertensive drugs and frequency of side effects, the values (mmHg) of systolic (SBP) and diastolic blood pressure (DBP). Results: Out of 79 patients, 48/79 (60.8%) were males and 31/79 (39.2%) were females. The median age in males was 53 years (IQR=48 to 55 years), in females 53 years (IQR=49 to 56 years). There was no statistically significant difference in median age between males and females (P=0.368). There is a statistically significant difference in the values of SBP [χ2(5)=312.296, P<0.001] and DBP [χ2(5)=216.051, P<0.001] over a period of six months follow-up. The drug side effects were noted in 9/79 (11.4%) patients between 1-2 months, in 6/79 (7.6%) between 2-3 months, in 1/79 (1,3%) between 3-4 months. The most common side effect was cough (11/79 or 13.9%) associated with the combination of ACE inhibitor and thiazide diuretics. In 5/79 (6.3%) patients there were reports of: flushing, palpitations, headache, dizziness and leg edema associated with Ca blockers. Conclusion: The most common side effect of antihypertensive treatment was cough (13.9%) associated with the combination of ACE inhibitor and thiazide diuretic.
INTRODUCTION
Hypertension is a common comorbidity of diabetes mellitus (DM) and it occurs in 20-60% of people with DM (1) .The application of combined antihypertensive treatment proved to be necessary in diabetics, kidney patients and patients at high risk, and generally whenever a lower blood pressure (BP) value is desired (2) . In view of the increasing number of available antihypertensive agents, clinicians are faced with the need to become familiar with the potential side effects of these drugs. In order to minimize the incidence of drug-induced side effects, several facts need to be remembered: (a) the most important side effect of diuretics is hypokalemia, which can cause cardiac arrhythmias and may be dangerous in patients who are taking digitalis, ones with chronic arrhythmias and acute myocardial infarction; (b) β-blockers (β-B) can induce bronchoconstriction, peripheral vasoconstriction, glycogenolysis, inhibition of insulin secretion and sometimes induce severe bradycardia. They can also cause cold limbs, faster fatigue, nightmares, insomnia and depression; (c) calcium channel blockers (CaB) of the first generation, particularly nifedipine, a representative of dihydropyridine, causes a number of side effects: sudden drop in blood pressure (BP) value, sympathetic activation and reflex tachycardia, especially dangerous in coronary patients, facial flushing and headache; (d) angiotensin-convertin enzyme (ACE) inhibitors' side effects are rare and the two of them are specific: cough andangio neurotic edema. They are associated with the action on the bradykinin system (3).
Unfortunately, adverse antihypertensive drugs reactions cannot always be predicted from the pharmacological profile and only prolonged clinical experience will reveal their's adverse effects.
In this study, we evaluated the incidence of adverse effects of antihypertensive drugs in patients with diabetes mellitus type 2 and hypertension.
PATIENTS AND METHODS
A clinical, prospective study was conducted at the Department of Internal Medicine, Clinical Center University of Sarajevo (CCUS) during 2012-2013. Th e study was conducted with the consent of the Ethical Committee of the CCUS.
Patients
Th e study included 79 patients with DM type 2 and hypertension, randomly selected by systematic sampling who were followed over a period of six months. Th e inclusion criteria were: patients with DM type 2 and arterial hypertension (blood pressure measured in the sitting position after at least 5 minutes rest, average of three readings at the last run-in-visit, should range from 140 to 179 mmHg systolic or from 90 to 109 mmHg diastolic-grades 1 or 2 of hypertension; women or men with uncomplicated hypertension within the age range from 40 to 60 years old, because of the lesser likelihood of the existence of any vascular incidents as a complication of DM. Th e exclusion criteria were: a history of cardiovascular disease; secondary hypertension; renal dysfunction; recent treatment with two or more antihypertensive drugs or a contraindication to discontinue blood pressure lowering agents; severe non-cardiovascular disease; known contraindications for the fi rst-line study medications, pregnant and lactating women. All participants signed informed consents for participation in this study.
Methods
Patients were assessed at baseline and once a month by measuring following parameters: types of used antihypertensive drugs and frequency of side eff ects, the values (mmHg) of systolic (SBP) and diastolic blood pressure (DBP). Th e incidence rate of adverse eff ects was the primary outcome variable calculated according to the formula: the number of new cases with side eff ects that occurred during a specifi ed period of time/the total number of treated patients during that period of time expressed as a percentage. Sitting SBP and DBP (average of three readings) were secondary outcome variables.
Statistical analysis
Th e Kolmogorov-Smirnov statistic Test with a Lilliefors signifi cance level was used for testing normality. In case of categorical variables, counts and percentages were reported. A P-value <0.05 was considered as signifi cant. Th e Friedman Test is used to test diff erences between diff erent periods. Post-hoc analysis with Wilcoxon Signed-Rank Tests was conducted applying Bonferroni correction, resulting in a signifi cance level set at P<0.003. Statistical analysis was performed by using the Statistical Package for the Social Sciences (SPSS Release 21.0; SPSS Inc., Chicago, Illinois, United States of America) software.
RESULTS
Out of 79 patients, 48/79 (60.8%) were males and 31/79 (39.2%) were females (χ 2 (1)=3.658; P=0.056). Th e median age in males was 53 years (IQR=48 to 55 years) and in females was 53 years (IQR=49 to 56 years). Th ere was no statistically signifi cant diff erence in median age between males and females (P=0.368).
Th e most commonly proscribed therapy was the combination of three antihypertensive drugs (35.4%), followed with the combination of four antihypertensive drugs (31.9%), two antihypertensive drugs (15.7%) and fi ve antihypertensive drugs (9.1%). Th e monotherapy is used in 5.1% and the combination of six antihypertensive drugs in 2.8%.
Th e drug side eff ects were noted in 9/79 (11,4%) patients between 1-2 months, where eight subjects 8/79 (10.1%) were reported with cough associated with ACEI + TD, while one patient 1/79 (1.3%) experienced dizziness and fl ushing associated with Cab. Between 2-3 month, the drug side eff ects were noted in 6/79 (7,6%), where three patients 3/79 (3.8%) were reported with cough, associated with ACEI + TD, while the other three patients, 3/79 (3.8%) experienced side eff ects associated with CaB: allergies, headache, fl ushing and leg edema.
Dizziness and palpitations associated with CaB appeared between 3-4 months in one patient 1/79 (1.3%). Th e drug side eff ects were not recorded during 4-5 and 5-6 months periods.
At the beginning of the study, the median value of SBP was 150 mmHg (IQR=150 to160 mmHg), and after six-month treatment was 125 mmHg (IQR=120 to130 mmHg), which represents a reduction of SBP for 25 mmHg. Th ere was a statistically signifi cant diff erence in the SBP values over the six-month use of the antihypertensive therapy (χ 2 (5) =312.296; P<.001). At the beginning of the study, the median value of DBP was 100 mmHg (IQR=90 to100mmHg), and after six months of treatment was 80 mmHg (IQR=80 to 85mmHg), which represents a reduction of DBP for 20mmHg. Th e DBP value in patients (n=79) signifi cantly changed during the six months of therapy with antihypertensive drugs (n=79) (χ 2 (5) =216.051; P <.001).
DISCUSSION
In this prospective study, we found that the most common side eff ect of antihypertensive treatment was cough (13.9%) associated with the combination of ACEI + TD used between 1-2 months and 2-3 months of follow-up. Between 3-6 month these antihypertensive drugs were used in 15.6%-16.9% of patients and there were no adverse eff ects associated with them during this period. A dry cough occurs in 10-15% of patients treated with ACE inhibitors, due to the accumulation of bradykinin, substance P and/or prostaglandin in the lungs (3), which coincides with our results. Th iazide diuretics are one of the cheapest and most commonly used antihypertensive drugs worldwide. Th iazides, however, have signifi cant tside-eff ect profi le and often, as monotherapy, are insufficient to normalize blood pressure value. Ng Lp et al. were conducted a retrospective study to identify patients who discontinued the use of ACE inhibitors and they found that 30.4% of patients discontinued the use of ACE inhibitors due to cough (4). Caldeira et al. conducted systematic review and meta-analysis to evaluate the tolerability of ARBs in patients with intolerance to ACE inhibitors and they found that ARBs had fewer cough events versus ACE inhibitors (5). In our study, the incidence of adverse reactions to CaB was 6.3%. Out of the total number of patients with adverse eff ects to CaB (n=5), two of them were females who experienced fl ushing. Kajiwara et al. study revealed that vasodilation-related adverse symptoms to dihydropyridine calcium channel blockers occurred signifi cantly more often in females than in males (OR 1.87, 95 % CI 1.28-2.71, p = 0.001) and furthermore, exclusively among females. Th e younger age group (<50 years) complained more frequently of vasodilation-related symptoms (OR 2.39, 95 % CI 1.02-5.59, p = 0.045) (6) . Peripheral edema, particularly of the lower limbs, is one of the most common adverse eff ects of dihydropyridine calcium channel blockers and may result in the need of dose reduction or drug withdrawal, both of which can adversely aff ect antihypertensive effi cacy (7). In our study, one patient had leg edema associated with CaB. In the study conducted by Luis MR, side eff ects such as: headaches and dizziness were more frequent in the group of olmesartan/hydrochlorothiazide compared to olmesartan group, hydrochlorothiazide group and the placebo group (8). Barrios et al. found that the treatment with medoksomilolmesartan, 40 mg/per day, was associated with a lower frequency of side eff ects compared to the combinational therapy of olmesartan medoksomil/hydrochlorothiazide (21.5% vs. 28.3%) (9) . In the study conducted by Pool J Let al., 1.346 patients were randomized into eight groups: valsartan (VAL) 160 and 320mg; hydrochlorothiazide (HCTZ) 12.5 and 25mg; VAL/HCTZ160/12,5;320/12,5; 320/25mg and placebo groups (10) . Each of these combinations was associated with a signifi cant reduction in SBP values and DBP values compared to monotherapy and placebo groups (all P<.001). Th e incidence of hypokalemia was lower in the combination of valsartan/hydrochlorothiazide (1.8%-6.1%) compared to monotherapy with hydrochlorothiazide (7.1%-13.3%). Th e study by Bangalore S et al. (11) quested whether the therapy with the targeted normal SBP value (<120 mm Hg) reduces the incidence of the large cardiovascular incidents in patients with type 2 diabetes and cardiovascular disease or additional risk factors. Th e total number of 4.733 patients with type 2 diabetes (10-year median), aged 40-88 years (mean 62 year), were randomized to intensive or standard therapy for achieving SBP<120 mmHg and<140 mmHg, respectively. Serious side eff ects, which are attributed to antihypertensive treatment, appeared in 77(3.3%) subjects with intensive therapy and in 30 (1.3%) patients with a standard therapy (P < .0001).
CONCLUSION
Th e most common side eff ect of antihypertensive treatment was cough (13.9%) associated with the combination of ACE inhibitor and thiazide diuretic. Th e optimal choice and antihypertensive drug dosage should be done in accordance with the guidelines, by taking into consideration all patients characteristics.
